
CLAIMS

1. Use of a compound of formula (1) in the manufacture of a medicament for treating cancer and/or reducing or preventing the appearance of metastases in a human patient afflicted with a cancer, wherein the compound is administered with a daily dose from 1 mg/kg to 80 mg/kg, and wherein the compound has the following formula (1):



(1)

wherein Y represents an oxygen, a sulfur or a selenium atom, preferably an oxygen atom,

Z represents O, S, Se, NH or a NR_6 group, wherein R_6 is an aryl or an optionally substituted alkyl group, preferably an oxygen atom,

R^1 represents a hydrogen atom, an optionally substituted alkyl group or an aryl group,

R^{2a} represents a hydrogen atom, halogen, azide (N_3), a carbonate or dithiocarbonate group, a 1H-[1,2,3]triazolyl group or a group —X—R2, wherein

X represents an oxygen, a sulfur, a selenium atom, a NH or NR_7 group, R_7 being an optionally substituted aryl or alkyl group; X preferably represents O or NH, and;

R2 represents an aryl group, an optionally substituted alkyl group, a hydrogen atom, a trichloroacetimidate group (-C(=NH)CCl_3), an acyl, formyl, sulfonyl, sulfinyl, tert-butyldiphenylsilyl, allyl group, a saccharyl, ester, amide, thioamide, sulfonamide group, or X-R2 represents a P(O)R_2R_6 group, in which R_2 and R_6 represent independently from each other an aryl group, an optionally substituted alkyl group, OH, an alkoxy or an aryloxy group,

R^3 and R^4 represent independently from each other an aryl, an optionally substituted alkyl group, an hydrogen atom, a trichloroacetimidate group, an acyl, formyl, sulfonyl, sulfinyl, tert-butyldiphenylsilyl group, an allyl, ester, amide, thioamide, sulfonamide group, or R^3 and R^4 taken together form a divalent radical of formula -R^3-R^4-, wherein -R^3-R^4- preferably represents an isopropylidene, benzylidene, diphenyl methylidene, cyclohexyl methylidene group, and their substituted analogues, for example a 4-methoxybenzylidene group, or a linear alkylene group such as an ethylene group,

R^5 represents a hydrogen atom or a hydrocarbon group comprising one or more heteroatoms, preferably selected from oxygen, sulfur or nitrogen, more preferably oxygen.

2. The use according to claim 1, wherein the compound is to be administered with a daily dose from 2 mg/kg to 70 mg/kg, preferably from 2 mg/kg to 60 mg/kg.

3. The use according to claim 1 or 2, wherein the cancer is selected from non-small-cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), breast cancer, oesophageal cancer, melanoma, gastric cancer, glioblastoma multiform, small bowel cancer, colorectal cancer, anal cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, hepatocarcinoma, preferably glioblastoma multiform, breast cancer and non-small-cell lung cancer, preferably glioblastoma multiform.

4. The use according to any one of claims 1 to 3, wherein the compound is to be administered orally.


5. The use according to any one of claims 1 to 4, wherein the compound is to be administered from 2 to 6 times per 24 hours, advantageously from 2 to 4 per 24 hours, to reach the daily dose.

6. The use according to any one of claims 1 to 5, wherein the compound is to be administered from 2 or 3 times per 24 hours, advantageously twice per 24 hours, to reach the daily dose.


7. The use according to any one of claims 1 to 6, wherein the compound is to be administered in a fasted or fed subject, in particular in a fed subject.

8. The use according to any one of claims 1 to 7, wherein the compound is of formula (1) with Y = Z = O.

9. The use according to any one of claims 1 to 8, wherein R^5 is selected from the following groups:



ou




wherein R^{14}, R^{15} and R^{16} represent, independantly from each other, a hydrogen atom, an aryl group, an optionally substituted alkyl group, a trichloroacetimidate group, an acyl, formyl, sulfonyl, sulfinyl, *tert*-butyldiphenylsilyl, allyl, ester, amide or a sulfonamide group, or R^{15} and R^{16}, taken together, form a divalent radical of formula $-R^{15}-R^{16}-$, wherein $-R^{15}-R^{16}-$ preferably represents an isopropylidene, benzylidene, diphenyl methylidene, or a cyclohexyl methylidene group, and their substituted analogues, for example a 4-methoxybenzylidene group, or a linear alkylene group, such as an ethylene group.

10. The use according to any one of claims 1 to 9, wherein R^1 is a phenyl group and/or X-R2 is OH and/or R^3 and R^4 represent a benzyl group.

11. The use according to any one of claims 1 to 10, wherein the compound of formula (1) is 3-Hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2λ5-[1,2]oxaphosphinane.

12. The use according to any one of claims 1 to 11, wherein the compound has the following Formula (I):



(I)

13. The use according to claim 12, wherein the compound of Formula (I) is in a crystalline form characterized by powder x-ray diffraction reflections at about 8.65, 16.06, 16.53, 19.16 and 21.05 ± 0.2 degrees two-theta.

14. The use according to claim 13, wherein the compound is further characterized by powder x-ray diffraction reflections at about 14.04, 17.69, 19.66, 22.02 and 25.12 ± 0.2 degrees two-theta.

15. The use according to claim 13 or 14, wherein the compound is further characterized by powder x-ray diffraction pattern as depicted in FIG. 1.